Alexandru Kimel, MD
Rheumatology · Teaneck, NJNPI 1992940860
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,910 of the $9,687 with a category attached, or 81.7%. Johnson & Johnson accounts for 83.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $4,554 and has fallen 90.0% since, to $457 in 2025.
Across 98 payments — averaging $98.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- Novartis$539
- Amgen$424
- Aurinia Pharma U.S., Inc.$125
- Genentech USA, Inc.$124
- Genentech, Inc.$76
- plus $319 from 11 others
What the payments were for
- Consulting fees$7,91082%
- Food & beverage$1,54416%
- Education$2332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $8,080 |
| Novartis | 30 | $539 |
| Amgen(2 entities) | 28 | $424 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Genentech USA, Inc. | 4 | $124 |
| Genentech, Inc. | 2 | $76 |
| AbbVie | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Invivyd Inc | 2 | $37 |
| Radius Health, Inc. | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $30 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| UCB, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Octapharma USA, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,687 in reported general payments places this provider in the 80th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 42 | $312,627 |
| Humira(Cf) PenAdalimumab | 34 | $237,816 |
| RinvoqUpadacitinib | 18 | $154,997 |
| ProliaDenosumab | 84 | $135,689 |
| SimponiGolimumab | 17 | $93,838 |
| ActemraTocilizumab | 28 | $91,971 |
| OrenciaAbatacept/Maltose | 23 | $83,843 |
| RemicadeInfliximab | 19 | $77,419 |
| Orencia ClickjectAbatacept | 11 | $62,969 |
| Teriparatide | 20 | $52,983 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 20 | $48,735 |
| Hydroxychloroquine Sulfate | 372 | $16,295 |
| MethotrexateMethotrexate Sodium | 233 | $9,385 |
| Celecoxib | 207 | $7,967 |
| Cevimeline Hcl | 15 | $4,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $424 | $184,424104 claims |
| Johnson & JohnsonSimponi, Remicade | $8,080 | $171,25736 claims |
| AbbVieRinvoq | $74 | $154,99718 claims |
| Genentech, Inc.Actemra | $76 | $91,97128 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $54 | $83,84323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Teaneck
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
- Anan HaijaGalloway$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.